Related Experiment Video

Updated: Aug 25, 2026

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
08:37

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Published on: April 21, 2015

Role of CD40 and B7 costimulators in inflammatory bowel diseases

Lino Polese1, Imerio Angriman, Marco Scarpa

  • 1Dipartimento di Scienze Chirurgiche e Gastroenterologiche P.G. Cévese, Clinica Chirurgica I, Università di Padova, Italy. linopolese@hotmail.com

Acta Bio-Medica : Atenei Parmensis
|April 2, 2004
PubMed

Insights

Investigating CD40/CD40 ligand and B7/CD28 costimulation in inflammatory bowel diseases (IBD) reveals potential antibody therapies. Targeting these pathways shows promise in animal models and ongoing human trials for IBD treatment.

Area of Science:

  • Immunology
  • Gastroenterology
  • Pharmacology

Background:

  • Inflammatory bowel diseases (IBD) pathogenesis involves immune cell costimulation.
  • CD40/CD40 ligand and B7/CD28 pathways are critical in immune responses.
  • Understanding these interactions is key for developing targeted therapies.

Purpose of the Study:

  • To analyze the costimulatory roles of CD40/CD40 ligand and B7/CD28 in IBD.
  • To evaluate their potential as targets for antibody-based therapies.

Main Methods:

  • Review of existing literature on CD40/CD40 ligand and B7/CD28 in IBD.
  • Analysis of animal models of colitis.
  • Consideration of ongoing and past clinical trials.

Main Results:

  • CD40/CD40 ligand interaction is implicated in IBD pathogenesis; anti-CD40L therapy effective in animal models.
  • B7.2 associated with ulcerative colitis (Th2 pattern), B7.1 with Crohn's disease (Th1 pattern).
  • Anti-B7.1 therapy effective in animal models, but anti-B7 therapy not yet tested in humans.

Conclusions:

  • CD40/CD40 ligand and B7/CD28 pathways represent promising targets for IBD antibody therapy.
  • Differential roles of B7.1 and B7.2 suggest distinct therapeutic strategies for Crohn's disease and ulcerative colitis.
  • Further clinical investigation of anti-B7 therapies is warranted.

More Related Videos

A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease05:08

A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease

Published on: March 1, 2022

Related Concept Videos

Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...